FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising an antibody-antibiotic conjugate compound for treating a bacterial infection caused by one or more of Staphylococcus aureus, Staphylococcus saprophytics or Staphylococcus simulans, containing WTA (teichoic acid of cell wall) β antibody, a pharmaceutical composition for treating a bacterial infection caused by one or more of Staphylococcus aureus, Staphylococcus saprophyticus or Staphylococcus simulans, method of treating bacterial infection in a patient infected with one or more of Staphylococcus aureus, Staphylococcus saprophyticus or Staphylococcus simulans, method for destroying intracellular Staphylococcus aureus in cells of a Staphylococcus aureus infected patient without killing host cells, a method for preparing an antibody-antibiotic conjugate compound, a kit for treating an infection, caused by Staphylococcus aureus, Staphylococcus saprophyticus and/or Staphylococcus simulans, and an antibiotic linker intermediate for preparing the antibody-antibiotic conjugate.
EFFECT: invention extends the range of products for treating a bacterial infection caused by one or more of Staphylococcus aureus, Staphylococcus saprophyticus or Staphylococcus simulans.
29 cl, 17 dwg, 6 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
| RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
